The global High Intensity Focused Ultrasound Therapy Market was valued at $82,000 thousand in 2020, and is estimated to reach at $398,826 thousand by 2027, registering a CAGR of 21.9% from 2021 to 2027. High-frequency sound waves are employed in High Intensity Focused Ultrasound Therapy Market to kill cancer cells. It can only treat a single tumour or a portion of a larger tumour; it cannot be utilised to treat tumours that are widespread. As a result, High Intensity Focused Ultrasound (HIFU) Market is ineffective in the treatment of malignant tumours. Ultrasound waves propagate through tissue medium as energy carriers in this therapy, which is new and emerging. Tumor ablation, hemostasis, thrombolysis, and targeted drug/gene delivery are all possible with HIFU therapy, which is completely non-invasive. Using high-frequency ultrasound waves, the therapy is also utilised to treat prostate cancer. Because of its non-invasiveness, sharp treatment margins, and low complication rates, it is widely employed in interventional oncology. Furthermore, over the projection period, the application of the technology in conjunction with other therapeutic and diagnostic modalities, such as targeted drug/gene delivery, robotic surgery, and molecular imaging, is predicted to develop and have a revolutionary clinical impact. Prostate cancer, kidney cancer, primary and secondary liver cancer, pancreatic cancer, and bladder cancer will all see increased occurrence, boosting the market’s growth. According to the American Cancer Society, there were around 161,360 new cases of prostate cancer diagnosed in the United States in 2016. Furthermore, the market’s expansion has been propelled by the rapid advancement of medical technology and its wide variety of applications in the treatment of uterine fibroids, neurological disorders, cosmetic medicine, and other conditions.